Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen, J&J Barred From Marketing Procrit, Aranesp Chemo-Anemia Benefit

Executive Summary

Amgen and Johnson & Johnson are no longer able to promote the impact of their respective erythropoiesis-stimulating agents Aranesp and Procrit on symptoms of anemia in cancer patients, FDA said

Related Content

Drug Safety Concerns Help Depress U.S. Sales Forecasts From IMS Health
Amgen Ties Increased Transfusions To ESA Scrutiny in NCD Review Request
“World Series” Trial: Verdict Against Mircera Gives Amgen ESA Market Hold
Reintroduction Of Treatment Target For ESAs For Kidney Failure?
Amgen Will Tap Experience With ODAC’s EPO Review To Tackle Renal Panel
EPO DTC Ads Create Impression Unsupported By Data, FDA And ODAC Agree
EPO Dosing Questions Left Unanswered; More Data, More Meetings Needed
Strange Bedfellows: Amgen, J&J Work Together In Advance Of EPO Meeting
Aranesp Trial May Allay EPO Concerns Despite Failing On Primary Endpoint



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts